Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: jake burns who wrote (438)	6/9/1998 7:14:00 AM
From: Robert DeHaven	Respond to of 1510

I am strapped in and ready to ride....boy am I PO'd I didn't just buy at the ask yesterday at 10 3/8.....instead I tried to buy at the bid all day and got bupkis....oh well...I too am hearing marvelous rumours....if only some of them would come true. good luck, bob

To: jake burns who wrote (438)	6/9/1998 7:42:00 AM
From: Manny Gugliuzza	Read Replies (1) \| Respond to of 1510

here is a short follow up e-mail from D. altman. Q. we (many) investors were expecting a corporate partner by the end of March, another quarter has now nearly passed. is there another time frame we can expect this to fall into? A. the company is moving forward with discussions as stated previously however i am unable to predict when the collaborations may be completed. when working with large pharmaceuticals there are many more levels of management that this must past through before completion. Q. has the company issued a formal application to the FDA, under the presidential guideline for life threatening illness, for approval of REMUNE? A. no. the company must complete the phase III trial before applying for FDA approval. Q. are there any other clinical studies scheduled to use human test subjects for IMNR'S vaccine now being tested on mice and primates? A. the monkey study needs to be completed first. Q. after the 10 million $ private placement and the cash ending balance of 4.5 million, how is the company financially suited to continue its R&D in the clinical studies? A. the company had 24 million at the end of last quarter(not including the private placement). the company has funds to carry it into 1999. anyone get any other information? very tight as always with the info. well the struggle goes on here with the 50 day MA. seems like we may win the battle here and leave the single digits behind. possible huge ( W ) formation looming on the horizon if a follow to the highs with this support continues. this would be the third, (cup and handle, reverse head and shoulders), and i do not know what else is left but this higher level base is very important to breakout from. good luck ar.